ALGOTHERAPEUTIX Announces First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Rare Disease Erythromelalgia
ALGENSCRIBE : ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement
AGS THERAPEUTICS Named among Business Worldwide Magazines 20 Most Innovative Companies to Watch in 2023
4P-PHARMA : Didier Landais est nommé CEO de 4P-Pharma
